Royalty Pharma Plc 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated September 2, 2020, details a material definitive agreement entered into by Royalty Pharma Plc (the "Company"). The filing announces the completion of a private offering of senior notes and the execution of related indentures and registration rights agreements.
Key Financial Metrics and Capital Structure
The Company completed a private offering of $6.0 billion in aggregate principal amount of senior notes across six maturities. The proceeds are intended to repay existing Term Loan A and Term Loan B facilities and cover transaction fees.
| Note Series | Coupon Rate | Maturity Date |
|---|---|---|
| 2023 Notes | 0.750% | September 2, 2023 |
| 2025 Notes | 1.200% | September 2, 2025 |
| 2027 Notes | 1.750% | September 2, 2027 |
| 2030 Notes | 2.200% | September 2, 2030 |
| 2040 Notes | 3.300% | September 2, 2040 |
| 2050 Notes | 3.550% | September 2, 2050 |
Debt Characteristics:
- Ranking: Senior unsecured obligations of the Company and Royalty Pharma Holdings Ltd. ("RP Holdings").
- Guarantees: Fully and unconditionally guaranteed by RP Holdings.
- Interest Payments: Semiannual on March 2 and September 2, commencing March 2, 2021.
Material Changes and Transaction Details
The primary material change is the refinancing of the Company's debt structure. The $6.0 billion in new notes will replace existing term loan facilities. The offering was conducted privately to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S.
A Registration Rights Agreement was signed with major underwriters (including BofA Securities, Citigroup, Goldman Sachs, J.P. Morgan, and Morgan Stanley) to facilitate a future registered exchange offer for the notes.
Outlook, Covenants, and Risks
Redemption Provisions:
- Make-Whole: Prior to the par call date, notes may be redeemed at a price equal to the greater of 100% of principal or the present value of remaining payments (make-whole).
- Par Call: After the par call date, notes are redeemable at 100% of principal plus accrued interest.
Change of Control: Upon a triggering event, holders may require the Company to repurchase notes at 101% of principal plus accrued interest.
Covenants: The Indenture limits the Company's ability to create liens, enter into sale/leaseback transactions, and consolidate or sell substantially all assets.
Events of Default: Include non-payment, covenant breaches, acceleration of other indebtedness, and bankruptcy. If triggered, holders of 25% of the principal may declare the debt immediately due.
Note: This filing does not provide specific revenue, profit, or cash flow figures for the reporting period, as it focuses solely on the debt issuance event.
Investor Verification Checklist
- Verify the exact amount of Term Loan A and Term Loan B facilities being repaid with the proceeds.
- Review the full text of the Indenture (Exhibits 4.1 and 4.2) for specific negative covenants and financial maintenance requirements.
- Confirm the status of the Registration Rights Agreement and the timeline for the exchange offer registration statement.
- Assess the impact of the new interest rates on the Company's future interest expense compared to the refinanced term loans.
- Check for any cross-default provisions linking these notes to other existing debt obligations.